AAAAAA

   
Results: 1-10 |
Results: 10
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
Authors: Vandamme, AM Houyez, F Banhegyi, D Clotet, B De Schrijver, G De Smet, KAL Hall, WW Harrigan, R Hellmann, N Hertogs, K Holtzer, C Larder, B Pillay, D Race, E Schmit, JC Schuurman, R Shulse, E Sonnerborg, A Miller, V
Citation: Am. Vandamme et al., Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up, ANTIVIR TH, 6(1), 2001, pp. 21-39
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting
Authors: Miller, V Vandamme, AM Loveday, C Staszewski, S Lundgren, J Youle, M Ait-Khaled, M Boucher, C Brun-Vezinet, F Dedes, N Giaquinto, C Hertogs, K Houyez, F Perrin, L Pillay, D Schmit, JC Schuurman, R Lange, J Banhegyi, D Biondi, G Broekhuizen, A Bush-Donovan, C Camacho, R Carlier, H Clavel, F Clotet, B Clumeck, N Colebunders, R De Clerq, K De Jaegher, JJ De Schrijver, G De Smet, K Hall, W Harrigan, R Hatzakis, A Hellmann, N Hoetelmans, R Holtzer, C Katlama, C Larder, D Loriaux, E McCreedy, B Mulcahy, F Opravil, M Phillips, A Ruiz, N Shulse, E Sonnerborg, A Soriano, V Steel, H Vella, S Williams, A
Citation: V. Miller et al., Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting, AIDS, 15(3), 2001, pp. 309-320
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients
Authors: Shafer, RW Hertogs, K Zolopa, AR Warford, A Bloor, S Betts, BJ Merigan, TC Harrigan, R Larder, BA
Citation: Rw. Shafer et al., High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients, J CLIN MICR, 39(4), 2001, pp. 1522-1529
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan
Authors: DeGruttola, V Dix, L D'Aquila, R Holder, D Phillips, A Ait-Khaled, M Baxter, J Clevenbergh, P Hammer, S Harrigan, R Katzenstein, D Lanier, R Miller, M Para, M Yerly, S Zolopa, A Murray, J Patick, A Miller, V Castillo, S Pedneault, L Mellors, J
Citation: V. Degruttola et al., The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan, ANTIVIR TH, 5(1), 2000, pp. 41-48
Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virologicalevaluation of the AVANTI 2 and AVANTI 3 studies
Authors: Maguire, M Gartland, M Moore, S Hill, A Tisdale, M Harrigan, R Kleim, JP
Citation: M. Maguire et al., Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virologicalevaluation of the AVANTI 2 and AVANTI 3 studies, AIDS, 14(9), 2000, pp. 1195-1201
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
Authors: Gartland, M Gerstoft, J Goebel, F Clumeck, N Cooper, DA Gatell, J Gazzard, B Gerstoft, J Goebel, F Lange, J Montaner, J Reiss, P Rozenbaum, W Vella, S Beveridge, A Cooper, DA Duncombe, C Gold, J Haberl, M Clumeck, N Luyts, D Montaner, J Rachlis, A Marina, R Gerstoft, J Wandall, JH Elbrond, B Molina, JM Pialloux, G Rozenbaum, W Beauvais, L Goebel, FD Staszewski, S Bruns, I Hug, M Reiss, P Lange, J Frissen, PHJ van der Ende, ME Bosboom, M Baas, C Milazzo, F Moroni, M Panebianco, R Clotet, B Artigas, JMG Gonzalez-Lahoz, J Leal, M Rodriguez-Lopo, C Gandarias, B Gazzard, B Johnson, M McKinley, S Page, V Watkins, K Sandstrom, E Belsey, E Darbyshire, J Chodakewitz, J Isaacs, R Jonas, L Meibohm, A Coughlan, M Fiddian, P Gartland, M Harrigan, R Larder, B Maguire, M Millard, J Moore, S Patel, K Shortino, D Tisdale, M Vafidis, I Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
Authors: Miller, V Ait-Khaled, M Stone, C Griffin, P Mesogiti, D Cutrell, A Harrigan, R Staszewski, S Katlama, C Pearce, G Tisdale, M
Citation: V. Miller et al., HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy, AIDS, 14(2), 2000, pp. 163-171
Antiretroviral therapy: 'the state of the art'
Authors: Montaner, JSG Montessori, V Harrigan, R O'Shaughnessy, M Hogg, R
Citation: Jsg. Montaner et al., Antiretroviral therapy: 'the state of the art', BIOMED PHAR, 53(2), 1999, pp. 63-72
Analysis of HIV-1 clinical trials: statistical magic?
Authors: Cooper, D Clumeck, N Montaner, J Harrigan, R Gerstoft, J Rozenbaum, W Goebel, FD Reiss, P Lange, J Vella, S Artigas, JMG Gazzard, B
Citation: D. Cooper et al., Analysis of HIV-1 clinical trials: statistical magic?, LANCET, 353(9169), 1999, pp. 2061-2064
Antiretroviral treatment in 1998
Authors: Montaner, JSG Hogg, R Raboud, J Harrigan, R O'Shaughnessy, M
Citation: Jsg. Montaner et al., Antiretroviral treatment in 1998, LANCET, 352(9144), 1998, pp. 1919-1922
Risultati: 1-10 |